Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Amortizatization of Intangibles (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Amortizatization of Intangibles for 10 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 92.4% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a 64.67% decrease, with the full-year FY2025 number at $11.4 million, down 56.84% from a year prior.
  • Amortizatization of Intangibles was $1.4 million for Q4 2025 at Iovance Biotherapeutics, down from $5.8 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $18.9 million in Q4 2024 to a low of -$4.0 million in Q3 2023.
  • A 3-year average of $4.9 million and a median of $5.5 million in 2024 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: surged 236.41% in 2024, then crashed 122.75% in 2025.
  • Iovance Biotherapeutics' Amortizatization of Intangibles stood at $8.0 million in 2023, then skyrocketed by 136.98% to $18.9 million in 2024, then tumbled by 92.4% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Amortizatization of Intangibles are $1.4 million (Q4 2025), $5.8 million (Q3 2025), and -$1.3 million (Q2 2025).